European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

NCT02852928 · tracked via the Priya Life Science Germany tracker

Sponsor

Matthias Griese

Phase

Observational

Started

2013-12

Last updated

2022-09-21

Condition(s) studied

Lung Diseases, InterstitialPulmonary Alveolar ProteinosisPulmonary EosinophiliaPulmonary FibrosisRespiratory Distress Syndrome, NewbornChild

Study summary

Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * all children with suspected or * verified diagnosis of ILD or * masquerading as ILD and * those with rare localized parenchymal lung diseases Exclusion Criteria: * other indication as inclusion criteria

Primary outcome measure(s)

Included subjects with specific diagnosis — 10 years
Number of recruited subjects

Trial sites (3)

Facility	City	Region	Status
Medizinische Hochschule Hannover	Hanover	Lower Saxony	Recruiting
Hacettepe University, Medical Faculty	Ankara	Sihhiye	Recruiting
University of Edinburgh	Edinburgh	United Kingdom	Recruiting

Other trials for the same condition

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis Active, not recruiting

Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD Active, not recruiting

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis Starting soon

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02852928 on ClinicalTrials.gov ↗ ← All trials in Germany